5 results
8-K
EX-99.1
URGN
UroGen Pharma Ltd
13 Jun 24
Regulation FD Disclosure
10:51am
.
ENVISION Single-Arm Pivotal Study Description Patient Population: Demographics and baseline characteristics reflective of general LG-IR- NMIBC patient … date of: üRecurrence üProgression üDeath UroGen Data on File 21 21 Overall Summary of Demographics in the Appendix
Robust Complet e Response Rat e
8-K
EX-99.1
URGN
UroGen Pharma Ltd
4 Mar 24
Regulation FD Disclosure
7:00am
primary chemoablation with UGN-102 is statistically superior to TURBT monotherapy
ATLAS Demographics and Safety Profile Treatment-emergent AEs were … generally mild to moderate Demographics and baseline characteristics were well balanced Similar safety profile to other between treatment arms studies
8-K
EX-99.1
URGN
UroGen Pharma Ltd
7 Feb 24
Regulation FD Disclosure
4:15pm
is statistically superior to TURBT monotherapy
ATLAS Demographics and Safety Profile Treatment-emergent AEs were generally mild to moderate Demographics … of Demographics and AE’s can be referenced in the Appendix
ATLAS Scorecard Highlights Clinically Meaningful, Durable Results for UGN-102 Overall and Relative
8-K
EX-99.3
URGN
UroGen Pharma Ltd
27 Jul 23
UroGen Announces $120 Million Private Placement of Ordinary Shares
9:57am
Alone 0.34 (0.15, 0.75) DOR UroGen Data on File 42 Various ATLAS 3-Month CR Rate Cohorts
Demographics and Baseline Characteristics Were Well … End of study visit End of study visit 56 SOC: Standard of Care
Summary of Demographics and Baseline Characteristics UGN-102 Characteristic Statistic
8-K
EX-99.2
URGN
UroGen Pharma Ltd
27 Jul 23
UroGen Announces $120 Million Private Placement of Ordinary Shares
9:57am
Response NCR: Non-Complete Response DFS: Disease-free Survival EOS: End of Study 24
ATLAS Demographics and Safet y Profile Treatment-emergent AEs were … generally mild to moderate Demographics and baseline characteristics were well balanced Similar safety profile to other between treatment arms studies
- Prev
- 1
- Next